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EXECUTIVE SUMMARY

Scott, Jessica. Working Toward Tetanus, Diphtheria, Acellular Pertussis in Every
Pregnancy: Protecting Our Most Vulnerable Population. Unpublished Doctor of
Nursing Practice capstone project, University of Northern Colorado, 2016.
Pertussis is a highly contagious, acute respiratory illness caused by the bacteria
Bordetella pertussis. This illness can last for several months and is most notable by a
paroxysmal cough on inspiration. Pertussis affects all ages and genders without
discrimination but has a disproportionately high rate of morbidity and mortality in infants
less than three months old. Protection from pertussis comes in the form of the tetanus,
diphtheria, acellular pertussis (Tdap) vaccine for adults and the diphtheria, tetanus,
acellular pertussis (DTaP) vaccine for children and infants.
The first whole cell pertussis vaccine was introduced in the 1940s, which brought
about a dramatic decrease in pertussis rates. This vaccine was associated with high
fevers and seizures in children. This version of the vaccine was removed from the market
in the 1980s and a safer acellular alternative was introduced. The acellular vaccine had
fewer side effects; however, immunity was noted to wane and pertussis incidence began
to increase. Infants who did not receive their first dose of Tdap until two months of age
were left vulnerable after exposure to adolescents and adults with pertussis. In October
2012, the Centers for Disease Control (CDC; 2013b), in conjunction with the American
Council for Immunization Practices (ACIP), released a national recommendation to
provide every pregnant woman with a Tdap vaccine between 27- and 36-weeks gestation.
iii

Vaccination during pregnancy would induce an immune response, creating antibodies
passed on to the fetus.
The purpose of this project was to improve the rates of Tdap in the pregnant
population at North Colorado Family Medicine (NCFM) in Greeley, Colorado. The
project included three specific interventions: (a) update of an existing provider reminder
tool located in every obstetric patients chart to include a prompt to give the Tdap vaccine
between 27 and 36 weeks, (b) inclusion of a patient-oriented CDC (2015c) factsheet in
the new patient packet given to every pregnant patient at the initial intake visit, and (c) an
educational session provided to the clinic’s medical assistants to offer education on the
purpose of the Tdap during pregnancy and their role in administering the vaccine under
the clinic’s standing order.
This project was implemented over a 14-week intervention period and results
were measured with comparison of pre- and post-intervention vaccine rates and
provider/medical assistant surveys. Pre-intervention rates were calculated after chart
review of all pregnancy and delivery codes for 2013-2015 after the initial
recommendation. Prior to the intervention, a total of 394 women delivered and 274 of
those women were given the vaccine (69%). Post-intervention chart reviews showed a
total of 74 pregnant women were seen in the intervention window and 65 of those women
were given the vaccine (88%). Post-intervention provider and medical assistant surveys
were distributed with a return rate of 48% for providers and 75% for medical assistants.
Survey results showed participating medical assistants and providers agreed or strongly
agreed the interventions would be beneficial in reminding them to provide the Tdap
vaccine to pregnant women between 27- and 36-weeks gestation. Indirectly, an increase
iv

in Tdap vaccination rates in pregnant women would likely decrease pertussis rates and,
therefore, the morbidity and mortality in infants less than three months of age. This
project was sustainable with future implications in practice as it utilized up-to-date
evidence in an effort to increase rates of adherence to national recommendations and
reduce rates of pertussis in a vulnerable population. As the clinic is part of a larger
system, the interventions can be disseminated to the different Banner health clinics and
have a wider impact on pregnant women throughout the western United States.
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CHAPTER I

PROBLEM STATEMENT

Introduction
Historically, with the introduction of vaccines in the United States and around the
world, there has been a decrease in the number and severity of deadly diseases. Vaccines
brought with them the eradication of small pox and polio, and near eradication of
diseases such as measles, mumps, and rubella. One disease, however, continues to
plague countries around the world despite the ability to vaccinate: pertussis. Pertussis has
had many names over the years; it was first named in the middle-ages as the kink, a
Scottish term for fit or paroxysm, or kindhoest from the German language meaning
child’s cough (Cherry, 1996). Cherry (1996) describes the history of pertussis; the first
epidemic was reported in Paris, France in 1578. The causative agent of pertussis was
unknown until 1906 when the Bordetella pertussis bacteria was finally isolated (Cherry,
1996). Over the century, pertussis has been called the 100-day cough due to its longevity
and whooping cough--so named from the classic inspiratory whooping noise made when
the cough is most severe (Cherry, 1996).
Prior to the introduction of the first pertussis vaccine in 1933, children were
affected by pertussis more than any other age group (Nitsch-Osuch et al., 2015). In this
pre-vaccination era, immunity in adolescents and adults came from natural immunity
gained from persistent exposure to the illness. Mothers would then pass this natural
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immunity gained from exposure to the disease to their infants through the transfer of
maternal antibodies through the placenta (Nitsch-Osuch et al., 2015). With the
introduction of the whole-cell pertussis vaccine--diphtheria, tetanus, and pertussis (DTP),
disease rates in children dropped and natural immunity that would protect adults and
adolescents was reduced. Childhood vaccines brought a significant decrease in the
incidence of pertussis, thus decreasing the overall morbidity and mortality associated
with this disease.
With the decreased incidence of pertussis, the nation’s focus shifted from concern
about the disease to concern about the vaccine. Severe local reactions at the vaccine site
and systemic reactions that included high fevers and seizures would bring about an antivaccination movement that would eventually end the mainstream use of the DTP vaccine
(Allen, 2013). The DTP vaccine was replaced with a safer alternative: the DTaP-diphtheria, tetanus, acellular pertussis. This new vaccine was purified, including only
killed pieces of the pertussis bacteria, and was introduced as a safer alternative that would
continue to protect the world from pertussis without the side effects of the vaccine. After
a short time, researchers realized this new, safer vaccine had come at a great cost--the
immunity did not last (Allen, 2013). Adolescents and adults were left unprotected,
marking the start of a rapid rise in pertussis that has persisted to present day. So began
the pertussis paradox: vaccine uptake increased with the safer acellular pertussis vaccine
but the incidence of pertussis started to climb (Allen, 2013).
While adults and adolescents with waning immunity have the highest disease rate,
infants less than three months of age are at the greatest risk. Nitsch-Osuch et al. (2015)
reported adults and older siblings are responsible for at least three-quarters of pertussis
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infections in infants. Infants cannot receive their first DTaP vaccine until two months of
age; with their developing immune systems, infants have the highest morbidity and
mortality associated with pertussis infection (Sawyer & Long, 2015). With this grim
realization, the Centers for Disease Control and Prevention (CDC) and Advisory
Committee on Immunization Practices (ACIP) have tried different strategies focused on
protecting infants from pertussis (CDC, 2014b). The first of these strategies included a
recommendation for a one time adult and adolescent booster of Tdap in 2005 to try and
reduce the incidence in illness in the population believed to be responsible for the highest
transmission to infants (CDC, 2014b). Another recommendation was released in 2008
for a one-time maternal immunization with Tdap in the immediate postpartum period
with the goal of protecting the mother and thus protecting the infant with whom she
would have the most contact (CDC, 2014b). It was determined that only protecting the
mother would not offer enough protection to the infant so a new strategy--providing a
booster to any unvaccinated adults or adolescents who would have contact with infants-was recommended in 2011 (CDC, 2014b). While effective, this strategy called
cocooning was not financially feasible on a grander scale and still left the infant without
any immunity of his or her own. (CDC, 2014b)
With emerging evidence of placental transfer of antibodies producing passive
immunity in infants, maternal immunization during pregnancy was determined a key
strategy to reduce the burden of pertussis in infants. In 2012, the CDC and ACIP
announced the recommendation to provide the Tdap vaccine to all pregnant women
between 27- and 36-weeks gestation regardless of previous vaccine status (Nesin, Read,
Koso-Thomas, Isaacs, & Meulen, 2015). Despite the recommendation from the CDC and
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ACIP as well as an increasing amount of evidence supporting the safety and efficacy of
the Tdap during pregnancy, national vaccine rates remained low and the incidence of
pertussis remained high. The purpose of this quality improvement project was to find an
effective means of increasing the uptake of the Tdap vaccine in pregnancy in the primary
care setting. This project addressed the following problem/patient/population,
intervention, comparison, and outcome (PICO) question: In pregnant women 27-36
weeks gestation, how does the implementation of an intervention bundle including patient
educational material, medical assistant education on existing standing order, and an
updated provider checklist with visual reminder tool compared with no change in current
practice affect Tdap vaccination rates in a large, urban primary care clinic?
Background
Pertussis is a highly contagious, acute respiratory disease caused by the bacteria
Bordetella pertussis or B. pertussis (Yeh & Mink, 2016). This disease is most notable by
its paroxysmal cough that can lead to post-tussive emesis and is characterized by the
“whooping” sound made on inspiration (Cornia & Lipsky, 2015). Pertussis is a gramnegative bacteria transmitted only between humans through respiratory secretions (Yeh &
Mink, 2016). It has a longer incubation period than most other viral respiratory
infections, ranging from one to three weeks, in stark contrast to typical viral infections
whose incubation period is usually only one to three days (Cornia & Lipsky, 2015).
There are three stages of pertussis: catarrhal, paroxysmal, and convalescent. Yeh
and Mink (2016) described the catarrhal stage as the early stage of pertussis where the
aerosolized droplets are most contagious and there is the highest risk for transmission.
During this stage, the illness most resembles an upper respiratory infection with mild
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cough, sneezing, watery eyes, and low-grade fever without the notable paroxysmal cough
and inspiratory whooping. It is assumed the similarities between the common cold and
the catarrhal stage of pertussis are primarily the reason for the high rates of transmission
from adults and adolescents to unprotected infants. The catarrhal stage typically lasts
between one and two weeks. The paroxysmal stage is where the severity of illness
increases and infants have the highest rates of mortality. Yeh and Mink described this
stage as distinctive--there are long periods of coughing without the ability to inspire,
causing the infants to become cyanotic and appear apneic. The paroxysmal stage is
where there is the typical inspiratory whoop and post-tussive emesis with coughing
spells. Infants are more at risk for complications at this stage with reported cases of
bradycardia, tachycardia, apnea, seizures, respiratory distress, respiratory failure,
pneumonia, hypotension leading to shock, renal failure, and death (Yeh & Mink, 2016).
This stage can last up to eight weeks where the paroxysmal cough worsens over the first
couple of weeks, remains at a high intensity for two or three weeks, and then gradually
lessens. According to Yeh and Mink, the last stage, the convalescent stage, can last
several weeks to months with symptoms gradually subsiding until resolved.
Treatment for pertussis varies depending on the age of the individual. Adults and
adolescents can be treated with antibiotics and usually recover at home without any
complications (Yeh, 2016). Children greater than one year of age may require some
more supportive therapy, such as fluid administration and nutritional support, but are
rarely hospitalized (Yeh, 2016). Infants less than six months old have a higher morbidity
and mortality associated with pertussis and often require supportive therapy in the
hospital setting. Infants who are in respiratory distress will be admitted to the hospital for
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supportive therapy where the diagnosis of pertussis is then established through clinical
indications or polymerase-chain reaction assays (PCR). Infants are placed in droplet
isolation and have an intravenous catheter established for parenteral fluids and antibiotics
(Yeh, 2016). Supportive therapy is continued until the infant is able to tolerate
paroxysmal coughing episodes without subsequent hypoxia requiring oxygen and is able
to eat independently (Yeh, 2016).
Prior to the introduction of the vaccine, the highest incidence of pertussis in the
United States occurred in 1934 with 250,000 reported cases (Cornia & Lipsky, 2015).
The first vaccine came in 1933 when the pertussis bacteria, suspended in a phenolyzed
saline, was introduced (Cherry, 1996). Over the next decade, scientists tried different
ways to create an effective vaccine. Then in the early 1940s, the whole cell vaccine was
introduced and a significant decrease was seen in the incidence of pertussis around the
world (Cherry, 1996). The whole cell organism was then combined with the tetanus and
diphtheria vaccine and the first DTP vaccine was mass produced and widely distributed
in developing countries. Cornia and Lipsky (2015) reported the DTP vaccine saw high
rates of localized and systemic reactions but by 1976, a disease that had once been
responsible for millions of illnesses and hundreds of thousands of deaths had decreased
dramatically in developing countries. In the United States, with the DTP vaccine
mainstreamed and widely used, the lowest reported incidence of pertussis in 1976 was
just 1,010 cases (Cornia & Lipsky, 2015).
The whole cell pertussis vaccine contained killed B.pertussis, diphtheria, and
tetanus (Allen, 2013). Side effects associated with the whole cell pertussis vaccine
included high fevers and seizures, which started an anti-vaccine movement in the early

7
1980s and led to manufacturers being sued and pulling out of the vaccine market (Allen,
2013). During this anti-vaccine movement, studies were done showing no identifiable
link between the vaccine and any permanent brain impairment but the damage to the
public’s perception of the vaccine’s safety was done, compelling manufacturers to start
looking at a safer version of pertussis immunization. The new vaccine replaced the
whole cell killed B. pertussis component with pieces of the bacteria that had been
purified to remove any possible contributors to the side effects experienced with the
whole cell vaccine (Allen, 2013). Soon after the DTP vaccine was taken off the market
and replaced with the diphtheria, tetanus, acellular Pertussis (DTaP) vaccine, it was
discovered the side effects of the original DTP vaccine were from an endotoxin released
from the bacteria’s cell membrane (Allen, 2013). The newer DTaP quickly had the
component associated with the endotoxin removed from the vaccine and became the new
and widely used replacement of the whole cell vaccine.
Allen (2013) wrote that soon after the wide-spread use of the acellular vaccine,
antibody responses to the vaccine were as high, if not higher than the whole cell vaccine,
without the fevers and seizures that started the anti-vaccine movement in the 1980s. All
was well until data started to emerge about increasing incidences of pertussis in
adolescents and young adults who had been among the first cohorts of children to receive
the DTaP. Cornia and Lipsky (2015) described how the emergence of pertussis in this
age group led researchers to the conclusion that the newer, safer acellular pertussis
vaccine had a waning immunity the whole cell pertussis vaccine did not have. This
waning immunity created a resurgence of pertussis in adolescents and adults with less
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severe disease symptoms, was often mistaken for other respiratory illnesses, and led to
unintended exposure to unprotected infants (Cornia & Lipsky, 2015).
Significance
Trending data from the introduction of the acellular pertussis vaccine in the mid1990s showed a steady increase in pertussis rates in the United States. The highest
numbers were seen in the peak epidemic of 2012 with 48,277 cases of confirmed
pertussis in all age groups. Of the total cases reported that year, more than half were in
adults and adolescents where immunity was believed to have waned from childhood
vaccinations (CDC, 2013a). There were 20 confirmed deaths from pertussis in 2012 and
15 of those deaths were in infants less than three months old, accounting for 75% of the
pertussis-related deaths that year (CDC, 2013a). There were 13 total deaths from
pertussis in 2013 and 12 of those deaths were in infants less than three months old,
accounting for 92% of the pertussis-related deaths (CDC, 2014a). In 2014, there were 13
deaths related to pertussis and eight of those deaths were in infants less than three months
old, accounting for 61% of the pertussis-related deaths that year (CDC, 2015a). The
burden of pertussis in infants is significantly higher than that of children, adolescents, and
adults. Infants with the disease have the highest rate of hospital admissions and carry the
highest morbidity and mortality rate (Goldfarb, Little, Brown, & Riley, 2014). The 2012
pertussis epidemic raised new concerns for healthcare providers on how to more
effectively protect this vulnerable population.
Financial Impact
Pertussis illness brings with it a heavy economic burden. The financial burden of
pertussis can be measured in the cost of treatment and hospitalizations as well as loss of
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productivity for those caring for the ill. Even in countries that have implemented
vaccination programs targeted at reducing pertussis illness, the persistence of the
pertussis endemic remains a significant public health concern. The true economic burden
of pertussis is hard to measure as it is assumed this disease is widely underdiagnosed and
underreported. Greenberg and Caro (2005) offered some idea of the cost of pertussis on
an individual level. For infants younger than the age of two months, the estimated cost of
pertussis disease was $2,822, which would increase with hospitalization and
complications to as much as $6,337 per infant. The authors also reminded the readers
these costs were for direct care costs and did not include productivity and income lost
when parents were missing work to care for their sick child (Greenberg & Caro, 2005).
Caro et al. (2013) examined the true cost and burden of the pertussis illness. This
study found the highest direct medical costs of pertussis were in the infant population.
The direct medical costs reported by Caro et al. were in line with those reported by
Greenberg and Caro (2005) but this study expanded on the indirect costs of pertussis
illness by lost days of work. Caro et al. found the average number of days lost when
caring for an ill family member with pertussis was six days of work with an estimated
cost of $767 per family when caring for an ill family member at home and $1,025 per
family when caring for a hospitalized infant.
O’Brien and Caro (2005) reported costs of pertussis hospitalizations by age group.
Data were gathered from hospital discharge databases from 1,000 hospitals in four
different U.S. states between 1996 and 1999. The results of this study found infants less
than one-year-old made up the majority of pertussis-related hospitalizations and those
hospitalizations were costlier than the older cohorts. The mean cost of an average six-
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day hospital stay for infants was $9,586 compared to a mean cost of $4,729 for
adolescents and adults (O’Brien & Caro, 2005).
To determine whether or not a vaccine strategy would be cost effective, the first
step has been to define the value of life. This value in literature was often measured as
quality adjusted life years (QALY), which is a method of assigning value to years of life
gained through disease prevention and/or treatment. Lugnér, van der Maas, van Boven,
Mooi, and de Melker (2013) performed a cost-effective analysis by examining three
different vaccine strategies in an effort to reducing the burden of pertussis illness on
newborns and infants: neonatal vaccination, maternal vaccination, and cocooning. From
strictly a monetary standpoint, this cost-effective analysis found cocooning was more
cost-effective than the maternal vaccination strategy. With regard to QALY gained, the
maternal vaccine strategy found higher QALY gained for the maternal vaccination
strategy (Lugnér et al., 2013).
Terranella, Asay, Messonnier, Clark, and Liang (2013) conducted a study using a
cohort model that looked at all U.S. births in 2009 and analyzed cases of pertussis,
hospitalizations, and deaths of infants less than one-year-old. They also looked at the
direct and indirect costs of pertussis illness in infants less than one year of age. These
numbers were analyzed to simulate the cost of maternal vaccination versus the postpartum cocooning strategy and looked at cost-effectiveness and quality adjusted life year.
The results of this study found maternal immunization reduced pertussis rates by 33%
whereas postpartum vaccination reduced pertussis rates by 20%. Hospitalizations were
reduced by 38% with the maternal vaccination method and 19% by the postpartum
method. Deaths related to pertussis illness in infants less than one-year-old were reduced
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by 49% in infants whose mothers received the Tdap vaccine during pregnancy compared
with 19% whose mothers were vaccinated after pregnancy. Cost was calculated based on
QALY saved and was significantly lower for maternal immunization versus postpartum
vaccination--$414,523 versus $1,172,825, respectively (Terranella et al., 2013).
Improving Tetanus, Diphtheria, and Acellular Pertussis
Immunization Rates Using the Reach, Efficacy,
Adoption, Implementation, and Maintenance
Framework
Introduced in 1999, the purpose of the reach, efficacy, adoption, implementation,
and maintenance (RE-AIM) model was to give researchers a theoretical model to
evaluate how well an intervention would reach and impact a community (Glasgow, Vogt,
& Boles, 1999). It seemed relevant that health promotion interventions in the public and
community health settings were only as good as could be measured through effective
evaluation. A systematic review of the use of RE-AIM described the use of the
framework from early and planning stages of an intervention, providing guidance
throughout the process and a structured method for evaluation as valuable on the impact
of public health and community-based initiatives (Gaglio, Shoup, & Glasgow, 2013).
The purpose of RE-AIM is to determine the real-world applicability and viability through
methodical and standardized assessment as a way to ensure generalizability and
sustainability in the community and population (Virginia Tech, 2015). By carefully
reviewing the RE-AIM framework, Gaglio et al. (2013) described the most efficacious
use of this model is when all five dimensions are discussed individually and
comprehensively.
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Reach
Identification of a target population is among one of the first steps in initiating a
community-based intervention. The target population for this capstone intervention was
pregnant women at a large, urban primary care and family medicine clinic in Greeley,
Colorado. This group was chosen because improving immunization rates for tetanus,
diphtheria, and acellular pertussis (Tdap) during pregnancy would not only benefit the
mother but had the end goal of preventing pertussis illnesses in her unborn child. Reach,
the first evaluation dimension in the RE-AIM network, determined what percentage of
pregnant women targeted by this capstone would participate in the intervention. Prior to
initiation of this intervention bundle, it was estimated approximately 11% of the
population at the target clinic were being seen for pregnancy-related health maintenance.
The first goal was to reach 100% of the target population by providing every pregnant
patient with educational material regarding the safety and efficacy of the Tdap during
pregnancy at their initial intake visit. It was determined the percentage of pregnant
women who participated (received the vaccination) also depended on education provided
to medical assistants and providers. The optimal way to reach 100% of medical
assistants was to attend two required monthly meetings and provide verbal education
regarding an existing standing order to provide every pregnant patient between 27 and 36
weeks with a Tdap booster. To reach the providers, the intervention thought to have the
most impact was to update an existing provider checklist that would be placed in every
pregnant patient’s physical obstetrics chart.
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Effectiveness
The RE-AIM framework (Virginia Tech, 2015) defined an effective initiative or
intervention as having a positive impact on the quality of life and health outcomes of
individuals, communities, and populations. The effectiveness of any intervention
describes the end result at the individual level, i.e., the target population was reached and
participated and there were positive outcomes (Glasgow et al., 1999). The goal of this
intervention was to increase Tdap rates in an effort to decrease the rates of pertussis in the
infant population by offering passive immunity through the transference of maternal
pertussis antibodies. Pertussis does not discriminate. It affects individuals of all ages,
races, ethnicities, and cultures. It does not target specific populations based on socioeconomic status, income levels, or educational levels. Children, adolescents, and adults
who are infected by B. Pertussis can be sick for weeks or even months but typically
recover without any long-term sequela. On the other hand, infants have a longer duration
of illness, can have lengthy and costly hospitalizations, and have the single highest rate of
mortality from pertussis (Cornia & Lipsky, 2015). The effectiveness of this intervention
bundle was intended to improve Tdap vaccination rates at the individual level, increase
the likelihood of population-based generalizability, and to affect vaccine rates at a
national and global level. Preventing illness in newborns and infants through maternal
vaccination will have a long term impact on the health outcomes of individuals,
communities, and populations, as well as having a positive economic impact by reducing
vaccine preventable illnesses that can lead to costly hospitalizations and death.
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Adoption
Adoption of the intervention bundle was measured at the organizational level
through compliance of all clinic staff, medical assistants, and providers. Adoption differs
from reach in that it measures use and compliance in the setting and at community and
population-based levels; reach looks only at the individual level. Use of the Tdap
vaccine during pregnancy has been well-researched and is backed at local, state, national,
and global levels through widespread recommendations by the National Institutes of
Health (NIH), Centers for Disease Control (CDC), American College of Obstetricians
and Gynecologists (ACOG), World Health Organization (WHO), and various other
institutions around the world (CDC, 2013b). The plan for adopting this intervention was
assessed through medical assistant and provider surveys. The surveys assessed the
effectiveness of the medical assistant educational sessions to evaluate the intervention as
well as any barriers the medical assistants found when ordering and giving Tdap vaccines
to pregnant patients. The providers were also given a survey to assess the effectiveness
of the provider reminder tool and CDC (2015c) pertussis factsheet as well as barriers and
opportunities for improvement.
Implementation
Implementation is different from adoption and/or effectiveness in that it looks at
how well or not a program was initiated as originally intended (Glasgow et al., 1999).
Planas (2008) further described implementation as having intervention fidelity or holding
true to/committing to implementing an intervention as planned and proposed. The
intervention for this capstone consisted of three quality improvement strategies
implemented at the provider and medical assistant levels in an effort to increase
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compliance and rates of Tdap during pregnancy. The interventions are described in
greater detail in Chapter III but in summary, they included an update to an existing
provider reminder checklist in use prior to the intervention, two educational sessions for
medical assistants regarding the use of an already existing standing order that included
Tdap during pregnancy, and the inclusion of a CDC authored educational handout
discussing the safety and efficacy of the vaccine during pregnancy in pre-existing patient
education packets. To maintain intervention fidelity, the same educational material was
provided to all pregnant patients, the education provided to the medical assistants was
done at the monthly meetings using the same educational PowerPoint, and the current
checklist used by providers was updated to ensure each provider was given the same
information. The purpose of each intervention was to enhance practices already
established in this clinic to improve the likelihood of maintenance.
Maintenance
Maintenance refers to long-term outcomes and sustainability at both the
individual and organizational levels (Planas, 2008). Maintenance of this quality
improvement project at the individual level was reflected by increased compliance in
receiving the vaccine at the right interval, which was intended to lead to a reduction in
pertussis rates in northern Colorado. Measuring maintenance at the individual level
could only be completed by measuring compliance as measuring associations between
the vaccine and decreased pertussis rates were out of the scope of this project.
Maintenance at the organizational level was reflected in the increased rates of the Tdap
vaccine given during pregnancy and was measured through retrospective chart review.
Planas (2008) described several factors that influenced the long-term uptake and success
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of an intervention. The first factor described was the manner in which the site was
initially approached with the intervention plan. Interventions rooted in a research nature
were determined to have a lower likelihood of long-term success as the participants often
saw the interventions and results as short term. Interventions such as this one, which was
approached as quality improvement, were often viewed more as long term with a higher
likelihood for adoption and compliance (Planas, 2008). This intervention was meant to
be long term as it was not a practice change but rather an update and improvement of
interventions already in place. This quality improvement project used key personnel who
were already in place and described as being vital to successful implementation and
maintenance (Planas, 2008). The last factor described by Planas was the meaningfulness
of the intervention to stakeholders. Stakeholders in this intervention were pregnant
women, medical assistants, and clinic providers. This intervention was anticipated to be
meaningful to the majority of pregnant women as this intervention provided optimal
protection to newborn infants from pertussis. Providers and medical assistants, with the
understanding they were providing a meaningful service, were predicted to maintain this
practice for the benefit of their individual patients, families, and communities.
Project Objectives
This intervention plan focused on providing resources and education to office
providers including physicians, nurse practitioners, and medical assistants. There were
three primary objectives for the project:


Update and improve current practice to increase the rate of Tdap
immunizations in pregnant women at North Colorado Family Medicine.
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Increase provider awareness and compliance with the national
recommendations of providing every pregnant patient with a Tdap vaccine
between 27- and 36-weeks gestation.



Increase medical assistant awareness and compliance with current standing
order to administer all pregnant patients with Tdap vaccine.

Intervention methods were implemented and evaluated based on these three primary
objectives and are described in more detail in the methods section.
Congruence of Intervention Plan with Organization’s
Strategic Plan
North Colorado Family Medicine is part of a larger system (Banner Health) with
clinics located in Arizona, Alaska, California, Colorado, Nebraska, Nevada, and
Wyoming (Banner Health, 2016a). Banner Health (2016a) considers itself one of the top
nonprofit organizations in the country--their primary focus being to excel in their mission
to make a difference in the lives of every person who interacts with the system. Banner
Health describes its strategic plan as providing the best care and health services to
communities it serves rather than just focusing on generating profits. By following this
strategic model, Banner Health reinvests all of the money earned into updating
technologies, attracting provider talent, paying employee salaries, and improving every
clinic and hospital to the highest standards. Banner Health (2016a) describes in their own
words their mission, vision, and values:
Mission. To make a difference in people's lives through excellent patient care
(para. 1).
Vision. We will be a national leader recognized for clinical excellence and
innovation, preferred for a highly coordinated patient experience, and
distinguished by the quality of our people (para. 7).
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This quality improvement project sought to align with the strategic plan, mission,
and vision of Banner Health by providing the safest and most up-to-date care to pregnant
women and their unborn children. The Tdap in every pregnancy is a national initiative
supported by research regarding the safety and efficacy of the vaccine and is a relatively
low cost and easy initiative with long-lasting benefits (National Foundation for Infectious
Diseases [NFID], 2014).
Summary
Pertussis is a respiratory illness that is gravely dangerous to infants less than three
months old. There have been 35 reported deaths in infants less than three months old
related to pertussis in the last three years in the United States (CDC, 2103a, 2014a,
2015a). Infants in this age range are highly susceptible to this illness because the first
immunization protecting babies from pertussis is not given until two months of age, the
full series is not completed until 12-18 months of age, and a booster shot is given
between four and six years old (CDC, 2015c). Adults, older children, and adolescents act
as the primary source of infection to these newborns and young infants as the early
symptoms in adults and adolescents often present as the common viral cold. Vaccinating
every mother with the Tdap vaccine during pregnancy offers passive immunity to the
newborn for the first two months of life until the first Tdap vaccine can be safely
administered (CDC, 2015b). Care of the pregnant patient is done in many settings
including obstetric offices, family care clinics, and hospital settings. Vaccines are
commonplace in most office settings and it is assumed the majority of providers are
knowledgeable about the safety and efficacy of the Tdap vaccine. Pregnant women rely
on their providers to maintain the most up-to-date knowledge regarding the
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recommendations, safety and efficacy of vaccines. In following the most updated
recommendations, providers have a responsibility to discuss the Tdap vaccine with every
pregnant patient, reduce vaccine hesitancy with increased patient education during office
visits, and then offer and administer the vaccine to every pregnant patient.
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CHAPTER II

LITERATURE REVIEW

A literature search was conducted using PubMed, CINAHL, Cochrane library,
and Google Scholar. The search was done using various combinations of the following
key words and phrases: immunizations in pregnancy, Tdap in pregnancy, pertussis and
pregnancy, safety of Tdap immunization in pregnancy, pregnancy outcomes and Tdap,
immunizations and birth outcomes, immunogenicity of Tdap in pregnancy, vaccine
hesitancy and pregnancy, Tdap vaccine uptake and pregnancy, vaccine perceptions and
pregnancy, vaccination improvement strategies and Tdap, epidemiology and pertussis,
and effectiveness of Tdap in pregnancy. For the scope of this project, the entirety of
literature regarding Tdap vaccines during pregnancy was not included and studies were
chosen based on relevance to the current project. The literature review parameters
included only studies published in the last five years and all types of studies were
included. Studies from different countries were included based on relevance to the
current project. Studies were sorted into the following categories: vaccine safety, vaccine
effectiveness, immunogenicity, vaccine hesitancy, and vaccine uptake improvement
strategies.
Vaccine Safety
Five studies and one systematic review were included that assessed the safety of
the Tdap vaccine in pregnancy. Different outcomes measured included unspecified
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adverse events, infant growth and development, small for gestational age (SGA), preterm
birth, major malformations, chorioamnionitis, Apgar score, cord blood pH, hypertensive
disorders in pregnancy, and spontaneous abortion and stillbirth rates.
Kharbanda et al. (2014) measured different obstetric outcomes in mothers and any
adverse events in newborns just after birth. Specific events and outcomes measured were
SGA births, chorioamnionitis, preterm birth, and hypertension in pregnancy. This study
was a retrospective, observational cohort study that measured the outcomes of 123,494
women between 2010 and 2012. Data for this study were pulled from the California
Vaccine Safety Datalink database. Of the 123,494 women studied, 26,229 received the
Tdap vaccine during pregnancy. No association was found between the Tdap vaccine
and any adverse obstetric or birth outcomes.
Kharbanda et al. (2016) measured adverse outcomes in a large observational study
of women who received the Tdap vaccine between 2007 and 2013. Specific outcomes
included neurologic events, thrombotic events, new onset proteinuria, gestational
diabetes, cardiac events, and thrombocytopenia. Data were collected from the California
Vaccine Safety Datalink. No acute adverse events were measured in the cohort of
women who received the vaccine during pregnancy.
In a retrospective cohort study, Morgan et al. (2015) compared pregnancy
outcomes among women who received Tdap during pregnancy, women who did not
receive Tdap during pregnancy, and multiparous women who had received Tdap in a
previous pregnancy within the last five years. Outcomes measured were rate of
stillbirths, major malformations, chorioamnionitis, five-minute Apgar score, and cord
blood pH. The study did not find any increase in adverse outcomes in the group that
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received the Tdap vaccine during pregnancy; however, the study did find significantly
increased rates of preterm birth and SGA births in the unvaccinated group.
Munoz et al. (2014) conducted a phase 1-2, randomized, double-blind, placebocontrolled clinical trial measuring outcomes in women who received the Tdap
immunization between 2008 and 2012. The primary outcomes looked for any adverse
outcomes with receipt of the vaccine but were not specific. The study also measured
post-partum pertussis illness and the growth and development of the infant through the
first 13 months of life. There were no measurable adverse events after receipt of the
Tdap vaccine during pregnancy and growth and development were similar in all groups.
In a retrospective cohort study that looked at 138 women who had received the
Tdap vaccine during pregnancy, Shakib et al. (2013) measured birth outcomes including
rates of preterm births, spontaneous abortions, and SGA births. This study found no
increased risk for preterm birth, spontaneous abortion, and SGA birth for women who
had received the Tdap vaccine during pregnancy.
One systematic review included in this literature review related to the safety of
the Tdap vaccine during pregancy. Keller-Stanislawski et al. (2014) looked at the overall
safety of vaccines during pregnancy and was not restrictive to Tdap. After review of
literature from 1946 to May 2013, it was concluded the benefit of antenatal vaccines
outweighed any potential risks with the exceptions of the live influenza and live
mumps/measles/rubella vaccines. No safety concerns were specifically identified for the
acellular pertussis.
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Vaccine Effectiveness
This literature search included two studies that looked at the effectiveness of the
maternal Tdap vaccination in reducing the incidence of or preventing pertussis illness in
infants. In a case-control study conducted between October 2012 and July 2013, Dabrera
et al. (2015) looked at rates of pertussis infection in infants of mothers who received the
Tdap vaccine during pregnancy versus the rate of infants whose mothers were
unvaccinated. There were 58 cases of pertussis; only 10 of the mothers had received the
Tdap vaccine during pregnancy whereas 39 of the 55 mothers in the control group had
received the vaccine. This study found a 93% vaccine effectiveness rate in mothers who
had received the vaccine versus mothers who had not received the vaccine. In an
observational study of pregnant women during a pertussis outbreak in England in October
2012, Amirthalingam et al. (2014) looked at vaccine effectiveness by comparing vaccine
coverage in a group of women whose infants were diagnosed with pertussis versus the
general population of pregnant women. After widespread Tdap vaccination during
pregnancy, England saw a 79% reduction in infant deaths from pertussis--from 2.02 per
100,000 live births in 2012 (before the implementation of vaccination recommendation)
to 0.43 per 100,000 live births in 2013. With an estimated vaccine effectiveness rate of
91%, recommendations to vaccinate all pregnant women between 27- and 36-weeks
gestation have continued as the preferred approach in the reduction of pertussis illness.
Immunogenicity
The literature search yielded seven original research studies that measured
immunogenicity, antibody levels in infants, the effect of timing on the levels and avidity
of maternal antibodies, the humoral and cell mediated response to the Tdap vaccine in
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pregnant and nonpregnant women, and passive immunity provided to the infant through
breast milk after antenatal vaccination. The primary outcome of five of the studies
looked at the transfer of maternal antibodies to the newborn after antenatal vaccination.
Four of these studies were conducted at the Bnai Zion Medical Center in Faifa,
Israel. A prospective study by Raya, Srugo, Kessel, Peterman, Bader, Gonen et al.
(2014) looked at the effect of the timing of maternal vaccination and how this could
affect antibody transference through measures of maternal serum and cord serum
antibody levels at birth. Women were vaccinated at different stages in pregnancy--one
group between 27 and 30 weeks, one group between 31 and 36 weeks, and the last group
from 36 weeks to term. Women who were vaccinated between 27 and 30 weeks had the
highest concentrations and women vaccinated after 36 weeks had the lowest
concentrations of maternal pertussis antibodies.
The next study by Raya, Bamberger et al. (2015) assessed the binding strength
between antibody and antigen and their relative avidity in relation to the timing of the
Tdap vaccine during pregnancy. The relative avidity of the maternal immunoglobulin G
to the pertussis toxin was measured between 23 and 38 weeks through newborn cord
serum. The higher the avidity of the pertussis toxin to the immunoglobulin G, the higher
the protective effects it would have on the infants. This study found the highest avidity
and, therefore, the highest level of protection to infants when their mothers were
vaccinated between 27 and 30 weeks.
In a prospective study, Raya, Srugo et al. (2015) wanted to assess how significant
the decline of pertussis antibodies would be in women who were vaccinated late in
pregnancy and whether or not there would be any lasting protection into subsequent
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pregnancies. The results of this study showed a significant decline in pertussis-specific
antibodies in maternal serum at nine months and 15 months postpartum. This study was
significant as it enforced the importance of receiving the Tdap vaccine in every
pregnancy regardless of previous vaccination status.
The last study by Raya, Srugo, Kessel, Peterman, Bader, Peri et al. (2014) wanted
to assess if there was any significant transfer of maternal pertussis-specific antibodies in
the breastmilk of women vaccinated with Tdap late in their pregnancy. Colostrum
pertussis antibody levels were measured and found to be significantly higher in women
who had received the Tdap vaccine after their 20th week. This study not only augmented
the data behind the support of vaccination during pregnancy but also the data supporting
breastfeeding.
Vilajeliu et al. (2015) conducted an observational study that sought to determine
maternal transference of pertussis-specific antibodies from mother to unborn infant.
Serum was measured in mothers prior to vaccination and then maternal and infant serums
were again measured after vaccination. It was found infants whose mothers were
vaccinated during pregnancy had higher levels of the anti-pertussis antibodies, enough to
protect them for at least the first two months of life.
Munoz et al. (2014) conducted a phase 1-2, randomized, double-blind clinical trial
whose primary outcome measured adverse events but whose secondary outcome
measured anti-pertussis antibody levels in infants at birth, two months, and after third and
fourth doses of DTaP. Antibodies measured at birth and two months were significantly
higher in infants whose mothers had received the Tdap vaccine and did not show any
decrease in response to the DTaP vaccine received in infancy. This study was significant
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because it showed the Tdap vaccine in pregnancy did not alter the infant’s response to
actively building immunity to the DTaP vaccine starting at two months.
The last study related to immunogenicity by Huygen, Caboré, Maertens, Van
Damme, and Leuridan (2015) measured humoral and cell-mediated immune responses in
pregnant and non-pregnant women. Antibody response levels were measured at one
month and one year after immunization and it was found pregnant and non-pregnant
women had similar humoral and cell-mediated responses to the vaccine. What was
significant about this study was the follow up at one-year post vaccination. Antibody
levels had waned to the extent that there would not be sufficient transfer of maternal
antibodies in any subsequent pregnancies, supporting the recommendation for repeat
vaccination with every pregnancy.
Vaccine Hesitancy
Regarding maternal perceptions and hesitancy of the Tdap vaccine during
pregnancy, this literature review found four studies and one systematic review that met
inclusion criteria. Healy, Rench, Montesinos, Ng, and Swaim (2015) conducted a
prospective, convenience survey of women during pregnancy at a large urban health
center. There were 796 surveys completed by pregnant women and 63 surveys by
providers assessing women’s attitudes toward their provider’s recommendations,
knowledge of recommended vaccines during pregnancy, and willingness to receive those
vaccines. Survey results showed pregnant women saw their provider as the most trusted
source of information (84%) and the majority of women would be willing to receive the
Tdap or influenza vaccine if educated on the vaccine and recommended by their provider
(83%).
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In a randomized, prospective study, Payakachat, Hadden, and Ragland (2016)
examined whether or not educational material, specifically a vaccine information sheet,
would improve maternal vaccine uptake of the Tdap vaccine. This study was conducted
at two urban women’s clinics where two groups were randomized to receive the CDC
(2015c) vaccine information sheet (VIS) and a modified VIS. There was no statistical
difference in the vaccine uptake between the two groups but the authors described that of
250 women who were included in the study--whether they received the VIS or the
modified VIS, there was a significant increase in uptake of the Tdap vaccine to 47%
compared to the previous rate of 13%. The authors described this study as significant as
the higher rate of uptake could be directly attributed to increased education provided to
the patients regarding vaccines during pregnancy.
Donaldson et al. (2015) conducted a cross-sectional survey of an ethnically
diverse group of 200 women who received prenatal care through a large public health
system in London. The purpose of this survey was to glean a better understanding of
what determined uptake of vaccines during pregnancy. Of the women surveyed, only
26% received the Tdap vaccine during pregnancy. Regarding this poor uptake, it was
determined only 34% of the women survey had even been offered the vaccine and only
24% of the women reported having a discussion with their practitioner regarding the
vaccine. This study found the greatest barriers to vaccine uptake were lack of
recommendation by providers and lack of accurate and timely information and education
regarding the vaccine during pregnancy.
Larson et al. (2015) and the World Health Organization’s (WHO) Strategic
Advisory Group on Experts (SAGE) on Immunization sought to define the various

28
reasons for vaccine hesitancy through the development of a survey tool. This survey tool
was valuable as a way of monitoring vaccine hesitancy--one of the major influences
keeping vaccine uptake low. These authors described the importance of their work in
separating the vaccine refusal group from the vaccine hesitancy group and focusing
efforts to improve uptake by targeting the vaccine hesitancy group. This article was
included not because it provided research data on vaccine uptake or hesitancy, but rather
a focus for researchers and providers to aim their efforts in improving vaccination rates.
The survey was sorted into key factors affecting vaccine uptake: contextual, vaccine
specific, and individual or group in relation to the decision to accept, delay, or refuse
vaccine recommendations.
A systematic review conducted by Wilson, Paterson, Jarret, and Larson (2015)
systematically assessed the most up-to-date literature regarding factors that influence
vaccine acceptance during pregnancy. A total of 155 articles were included in the search
looking at vaccine hesitancy regarding influenza, tetanus, and pertussis vaccines during
pregnancy. After review of these 155 articles, it was determined the factors affecting
uptake of vaccines during pregnancy most cited and relevant to pregnant women included
vaccine safety, vaccine effectiveness, no recommendation from provider, lack of
education regarding vaccines during pregnancy, access to vaccines, cost, and conflicting
recommendations. The barriers most cited by providers and other health care
professionals included inadequate training, reimbursement issues, and increased
workload. This systematic review on the global perspectives about vaccinations during
pregnancy offered more concise areas to target for vaccine improvement strategies.
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Vaccine Uptake and Improvement Strategies
This literature search yielded five studies that met inclusion criteria related to
vaccine uptake and improvement strategies. In a retrospective study of all women
delivering at one hospital between February and June of 2013, Goldfarb et al. (2014)
looked at the different demographics and what potential predictors influenced whether or
not women received the Tdap vaccine during pregnancy. The authors identified 1,467
women, 1,194 (81.6%) of whom received the Tdap vaccine during pregnancy. Through
multivariable logistic regression, three factors were found to influence women in
receiving the Tdap vaccine during pregnancy. The first factor found women were more
likely to receive the Tdap vaccine if they had already received the influenza vaccine
during their current pregnancy. The next variable showed Black women were least likely
to receive the Tdap vaccine. The last variable found women who delivered prematurely
were less likely to have received the Tdap vaccine. The purpose of this study was to
identify disparities in women who did or did not receive the Tdap vaccination during
pregnancy so further research could be conducted to minimize these disparities.
Forsyth, Plotkin, Tan, and von König (2015) reviewed all available literature
regarding which strategies were best for protecting newborns against pertussis. Available
strategies that have been used in recent years in an effort to reduce infant mortality
included Tdap in every pregnancy, immunizing all family members and anyone with
close contact to infants less than six months old (also known as cocooning), immunizing
both parents in immediate postpartum period, and immunizing only the mother in
immediate postpartum period. The authors of this article came from different countries
around the world as experts in the Global Pertussis Initiative (GPI; Forsyth et al., 2015).
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Through expert review of available evidence and literature, the GPI recommended Tdap
in every pregnancy as the most effective method for reducing the burden of pertussis on
infants. Cocooning and immunizing either parents, or only mothers, were considered
sufficient if Tdap was not or could not be given during pregnancy.
Healy, Ng, Taylor, Rench, and Swain (2015) reviewed uptake of Tdap in
pregnancy at a large urban hospital between April 2013 and June 2014. They reviewed
6,577 deliveries over the course of this one+ year period. In April 2013, the uptake of
Tdap during pregnancy was approximately 36%. Over the next year, provider
recommendations increased after the release of the ACOG toolkit as well as provider
trainings and reminders at meetings. With the implementation of these reminders, uptake
of Tdap increased from 36% to greater than 61% and sustained above that percentage
starting in November, 2013. Of note, women were categorized into different age ranges
and race/ethnicities and like Goldfarb et al. (2014), Black women were the least likely to
receive the Tdap immunization. The authors reported no clear reason why this group of
women was significantly less likely to receive the Tdap during pregnancy; further
research will be needed to discern the exact nature of this disparity. The overall
conclusion of this study suggested providing education to providers and provider
recommendations to patients are important factors in increasing the uptake of Tdap
during pregnancy.
Morgan et al. (2015) evaluated how using a best-practice alert in the electronic
health record (EHR) improved Tdap rates in pregnancy. In a groundbreaking effort to
reduce the burden of pertussis on infants, implementation of a best-practice alert
increased the uptake of Tdap in pregnancy from 48% to 96.8%. This best-practice alert
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was programmed to appear starting at 32-weeks gestation and continue to appear with
every visit until documented receipt of the vaccine or delivery occurred. Use of a bestpractice alert was clearly an advantageous tool to remind providers to give Tdap during
pregnancy but offered a logistical problem to groups of providers that could not get
approval for changes in or did not use an EHR.
In a systematic review of evidence, Bechini, Tiscione, Boccalini, Levi and
Bonanni (2012) analyzed use of the Tdap vaccine in high-risk groups such as pregnant
women, healthcare workers, newborns, and adolescents. Literature supported the use of
Tdap vaccine in pregnancy as a useful tool for reducing the burden of pertussis on the
infant population. Studies in immunogenicity showed a correlation with higher antibody
levels and a reduction in the risk of developing pertussis. This review supported the
current recommendation to provide the Tdap vaccine in every pregnancy as the primary
strategy for protecting infants from pertussis.
A cluster-randomized trial by Chamberlain et al. (2015) examined the results of a
multi-component antenatal vaccine package targeted at improving Tdap and influenza
uptake during pregnancy. Chamberlain et al. offered different strategies for increasing
vaccine rates during pregnancy including posters, brochures, lapel buttons, a vaccine
champion, education materials at the practice and patient levels, and provider education
at the provider level. This study did not find a statistically significant increase in the
uptake of vaccines during pregnancy but the authors believed that because it was
introduced late in the flu season, the results were confounded. One statistically
significant finding from this study was the correlation between provider recommendation
and vaccine uptake. Patients reported the single most convincing reason they would
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accept the Tdap or influenza vaccine was if the recommendation came from their
provider.
Summary
This literature review offered a summary of evidence regarding vaccine safety,
vaccine effectiveness, immunogenicity, vaccine hesitancy, and different strategies that
had been used to increase vaccine uptake during pregnancy. Studies looking at the safety
of the Tdap vaccine found no significant adverse events related to infant growth and
development, major congenital malformations, or any complications of pregnancy such
as preterm birth, spontaneous abortions, small or large for gestational age babies, or
stillbirths. Two major studies regarding vaccine effectiveness found the Tdap vaccine
given during pregnancy had a greater than 93% effectiveness rate at preventing pertussis
in infants less than two months old. Immunogenicity studies measured amounts of
antibodies passed from mother to infant through serum, colostrum, and breast milk, and
found infants received the highest number of antibodies if the vaccine was given between
27- and 36-weeks of pregnancy.
The studies examining vaccine hesitancy and uptake improvement methods were
important in the development of this capstone project. Multiple studies showed providers
were the most trusted source of information regarding vaccine safety and effectiveness;
provider recommendation yielded the most success in improving the rates of Tdap
immunization during pregnancy. There was no gap in evidence supporting the safety,
efficacy, or immunogenicity of the Tdap vaccine during pregnancy but was a gap in the
translation of this evidence to the care of pregnant women and their families. Therefore,
increasing provider adherence to national recommendations through targeted strategies
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was likely to yield the best outcomes and have the highest likelihood of success in
increasing rates of Tdap immunization during pregnancy.
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CHAPTER III

METHODS AND EVALUATION

Providing the Tdap immunization to mothers while pregnant reduces newborn and
infant complications from pertussis illnesses; yet, there remains a disparity between the
evidence and immunization rates. The exact nature of this disparity is not fully
understood but studies revealed provider recommendation remained the single most
effective way of increasing Tdap immunization rates in pregnancy. This project was a
quality improvement (QI) process that focused on updating and improving current
practice in an effort to increase the rate of women who would receive the Tdap vaccine
during pregnancy with the end result of preventing pertussis illness in newborns and
infants less than two months old. There were three primary objectives of this QI project:
(a) update and improve the current provider reminder tool, (b) increase provider
awareness of national recommendations, and (c) increase medical assistant (MA)
awareness and compliance with the current adult standing order for Td/Tdap vaccine in
adults. Each objective had an associated intervention, evaluation plan, and measurable
outcomes. The next section describes the setting, methods in detail, and evaluation plan.
Setting
North Colorado Family Medicine (NCFM) is a large family medicine clinic and
physician residency program located in the center of Greeley, Colorado. This family
medicine clinic sees patients of every age, gender, ethnicity, and socioeconomic status.
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As one of few family medicine clinics in Greeley that accepts Medicaid, these patients
comprise a large portion of the patient population. On a typical day, this clinic will have
19-20 patients per provider and 10-12 providers per day. The clinic consists of
attending/faculty physicians, residents of medical and osteopathic medicine, podiatry
residents, nurse practitioners, medical assistants, and ancillary administrative staff. North
Colorado Family Medicine is part of a larger hospital system in northern Colorado but
functions independently of the system with regard to day-to-day operations.
The first step in implementing the process improvement plan was to understand
what daily practice was and where there might be an opportunity for improvement.
North Colorado Family Medicine has a specific process in caring for pregnant patients
from planning and conception through birth. When women find out they are pregnant
and inform their providers or clinic staff, the first step is to schedule an obstetrics (OB)
intake visit that focuses mainly on history including the woman’s medical and surgical
history as well as pregnancy history and risk factors. Prior to the OB intake visit, the
clinic staff puts together a physical chart that includes questions related to history, past
pregnancies, a checklist regarding pregnancy education that is broken down by trimester,
and a checklist regarding specific interventions meant to guide the provider in avoiding
missing important diagnostic tests and interventions throughout the pregnancy.
This visit is an opportunity for the provider to answer questions and provide an
overview of pregnancy education items and the timeline for specific interventions. Lab
work is ordered at the OB intake visit; patients are escorted to the lab after their visit or
have the opportunity to come back prior to the next visit to have their blood drawn. After
the OB intake visit is completed, an OB physical is scheduled. This visit includes a
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complete physical exam, pelvic exam, pap smear if indicated, and review of lab work.
Once these initial visits are completed, the remainder of the visits are considered OB
maintenance visits where interventions such as immunizations and additional tests are
completed as part of those routine visits. The physical OB chart is pulled for every visit
including the routine maintenance visits as a resource for the provider so that it can be
referenced for timing and recommendations for testing and interventions.
Three interventions in this quality improvement project targeted the three primary
objectives. These interventions included an updated provider reminder tool that was
laminated and placed in the physical OB chart, an educational fact sheet on the Tdap in
pregnancy, and an educational meeting with medical assistants. Each intervention and
evaluation method are discussed in more detail in the next section.
Intervention Plan
Objective One: Provider
Reminder Tool
Considering current practice at North Colorado Family Medicine, the focus of this
intervention was to build on and improve current practice by utilizing a provider
reminder method already in use. Prior to the intervention, a provider reminder checklist
was in use per the description of current practice. This checklist was divided by
trimesters and included when to order specific diagnostic and lab tests as well as when to
initiate interventions. It was noted that this reminder checklist did not include
administration of vaccines during pregnancy as recommended by ACOG and the
Advisory Committee on Immunization Practices for the CDC (2016).
This checklist was widely used by providers and did not require any education as
to its existence. This checklist was printed on pink paper so it would stand out to
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providers, was laminated, and reusable in order to reduce waste. A picture of the
checklist used in previous practice can be found in Appendix A followed by the updated
checklist that replaced the previous list at the start of the project (see Appendix B). The
purpose of improving the previous checklist was to use a system already in place by
adding a visual reminder to providers to ensure the Tdap was given in every pregnancy.
Due to timing of this intervention, improving uptake of the influenza vaccine during
pregnancy was not formally included in this process improvement. However, at the
request of the medical director and nursing supervisor, a reminder to administer the
influenza vaccine was also added to the checklist. This was not part of this capstone and
was not evaluated but was added to the updated reminder checklist at the clinic’s request.
In an effort to improve the likelihood of providers recognizing the updated checklist, the
new list was printed on purple paper, laminated in the clinic, and given to administrators
in the medical records office who were responsible for putting together the physical
charts.
This clinic serves as a residency clinic in northern Colorado so it was expected
there would be gaps in knowledge between first year residents, second year residents,
third year residents, attending physicians, and nurse practitioners. The provider reminder
tool exists to bridge the knowledge gaps for newer providers and has been in existence at
the clinic for several years. Current practice has attending physicians, residents in their
second and third years, and nurse practitioners orienting newer residents to the use of the
physical chart used for OB patients so there was no need for this author to provide any
additional education regarding the use of the reminder tool.
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Objective Two: Educational Material
in Patient Information Packet
Prior to this intervention, the process was to provide every new obstetric patient
with an informational packet that included general pregnancy education, diet tips, local
classes, and available resources for all pregnant women. Information in these packets
was pre-approved by the nursing and medical directors for the clinic, put together by
existing ancillary administrative staff, and then distributed to patients at the time of their
intake appointment. Packets were given to the patients at check-in by the front desk staff
with the expectation that the provider doing the intake appointment would go over the
educational material with every individual patient. Prior to this intervention, these
packets did not contain any information regarding the safety and efficacy of vaccines
during pregnancy. Whether or not this education was routinely provided by each
provider was not formally evaluated.
To meet the second objective--increasing provider awareness and compliance
with the national recommendations of providing every pregnant patient with a Tdap
vaccine between 27- and 36-weeks gestation, a CDC (2015c) patient information sheet
(see Appendix C) was placed in all of the patient education packets. This information
sheet was available on the CDC website at no charge, printed at the clinic, and placed in
the packets by ancillary staff. Although this sheet was written with pregnant women as
the primary target audience, the objective of this intervention was to offer a reminder to
every provider of the existing recommendation to offer the Tdap in every pregnancy.
This intervention not only provided a visual reminder to start the conversation with the
patient regarding the Tdap during pregnancy at the initial OB intake visit but had an
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added benefit of augmenting patient education regarding the safety and efficacy of the
Tdap vaccine during pregnancy.
Objective Three: Medical Assistant
Education
The next tier of this intervention plan was to include two educational sessions
with the clinic’s medical assistants (MA). It was in the scope of every MA at North
Colorado Family Medicine (NCFM) to initiate the order for and administer all childhood
and adult vaccinations. The MAs at NCFM have two existing standing orders for adults
and children over seven-years-old, specifically for the Td/DTaP/Tdap vaccines. These
standing orders delineate that Tdap is to be given to pregnant women between 27 and 36
weeks (see Appendix D), and are based on the CDC Adult Vaccine Schedule (see
Appendix E). In observing the MA workflow, it was noted that Tdap vaccines during
pregnancy were rarely initiated by the MA; administration relied on the provider placing
the order and giving the MA a verbal order to administer the vaccine. At the start of this
project, it was assumed the percentage of MAs aware of this standing order was low.
Medical assistant education was provided at two separate mandatory staff
meetings. The MAs were presented with a short PowerPoint presentation that included a
picture of the standing order, the gestational ages at which the Tdap should be
administered during pregnancy, and background information on pertussis and why the
vaccine is so important to mothers and their unborn children (see Appendix F). The MAs
were instructed to defer all refusals to providers so education could be augmented by
physicians and nurse practitioners in an effort to improve Tdap vaccine rates.
The first educational sessions were offered at the first two mandatory meetings in
June and July. The initial meeting was targeted at the majority of the staff but accounting
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for possible sick days and staff turnover, the second educational session offered the same
PowerPoint and education to any new staff or staff who had missed the first meeting.
Attendance at the meetings was approved by the office manager as well as the nursing
director per the Statement of Mutual Agreement (see Appendix G).
No changes were made to the current standing order for the clinic as it covered all
adult and adolescent patients, including those who were pregnant, to receive the Tdap
vaccine. The purpose of the education provided to the MAs was to serve as a reminder of
a standing order for Tdap and pregnancy, provide education as to the timing of the
vaccine, and provide information regarding why the vaccine is important related to
decreased incidence of pertussis in the newborn and infant population. Increasing patient
education was an important piece of this intervention bundle; however, it was not
considered an objective as it was not feasible to evaluate the outcomes of this education
in the current patient population within the project timeframe.
Timeline


May 20, 2016--Capstone proposal defense



May 26, 2016--Submit to University of Northern Colorado Institutional
Review Board (IRB; see Appendix H)



June 13, 2016--Initiation of capstone quality improvement project following
IRB approval
o

Checklist updated and given to administration for printing and
laminating

o

PowerPoint completed for medical assistant education
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o

Patient educational material distributed to administrators for inclusion
into new patient OB packs by nursing director



June 13, 2016--Initiate chart review to determine current uptake of Tdap
during pregnancy in clinic from 2012 to present



June 14, 2016--First meeting with medical assistants and nursing director



July 5, 2016--Second meeting with medical assistants and nursing director



September 23, 2016--Completion of capstone quality improvement project



September 26, 2016--Distribution of evaluations to providers, residents, and
medical assistants



September 26, 2016--Initiate chart review for compliance of Tdap vaccine
uptake between June 13 and September 23, 2016



October 18, 2016--Capstone defense
Resources

This project did not require many resources for implementation, evaluation, and
maintenance. The three interventions included in this project were meant to build upon
and improve existing practice flow. This clinic consists of family medicine residents,
attending physicians, nurse practitioners, medical assistants, 28 patient exam rooms, four
minor treatment rooms, one major procedure room, in-house laboratory, nutritional
counselor, and in-house behavioral specialists. Ancillary administrative staff include
individuals who work at the front desk to check patients in, hand out and collect patient
information, update patient charts, and answer questions. There are individuals who
work to set up referrals, code charts, medical records, billing, residency services, and
office management. Office supplies are plentiful and included in the pre-existing budget.

42
The clinic has printers, scanners, copy machines, laminating machines, and computers inhouse that are provided for all staff and residents.
The cost to implement and maintain this intervention plan was minimal and was
absorbed into the pre-existing clinic budget. The educational materials were available at
no cost on the CDC (2015c) website. The link for this material was emailed to the
nursing director at her request and then the task of printing and placing in the new OB
packets was assigned to one of the administrative front desk staff. There was no need to
hire additional personnel as the task of making the packets had already been assigned so
the addition of the educational material was not an extra burden on the clinic.
Feasibility and Sustainability
This project was based on improving three activities already in place at North
Colorado Family Medicine (NCFM). Providing patients with educational material at the
OB intake visit was standard practice so the addition of the Tdap patient education
material served as supplemental material to reinforce the safety and efficacy of the
vaccine for pregnant patients and family members who might be hesitant or might not
even know of the recommendation to immunize every pregnant patient. This educational
material was available to all providers through the CDC (2015c) website free of charge.
Minimal additional costs included the paper, ink, and wear on the printer but these costs
were insignificant and did not require that additional materials be purchased. The time
spent on creating the new OB educational packets was standard at the clinic so the extra
time spent adding the Tdap educational sheet was negligible regarding the increased cost
to pay staff and decreased productivity. There was no intention to change practice
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regarding the use of the new pregnant patient educational material so this project should
be easy to maintain.
The education to the MAs was provided at a regularly scheduled monthly staff
meeting so no additional costs were required to pay staff to attend. The PowerPoint and
educational materials were completed by this author at no cost to the facility. This
intervention is sustainable as the use of standing orders is regular practice for the MAs in
this clinic setting.
In October 2014, the Public Health Service office through the CDC sent out a
letter to providers imploring their cooperation with their efforts in improving vaccine
rates during pregnancy (NFID, 2014). This letter (see Appendix I) reiterates to providers
how important it is to ensure the Tdap vaccine is provided in every pregnancy and
reminds providers that research confirms the provider recommendation for vaccines
during pregnancy as being essential in uptake (NFID, 2014). The CDC outlined steps for
increasing vaccination rates during pregnancy with the following four steps: (a) always
review the immunization status of every patient at every visit, (b) recommend any
vaccines due at the time of the visit if indicated by the adult vaccination schedule, (c)
administer the vaccine or refer to a provider who is able to administer the vaccine, and
(d) document all vaccines given in electronic health record as well as state registry if
possible. This call to action by the CDC reminds all providers of their duty to provide
vaccines during pregnancy in an effort to reduce mortality in infants from vaccine
preventable illnesses (NFID, 2014).
As per the Statement of Mutual Agreement (see Appendix G) and agreed upon by
the nursing director and medical director, the providers of North Colorado Family
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Medicine are invested in working toward ensuring Tdap in every pregnancy. It has been
demonstrated that pertussis prevention in infants is a priority of national organizations
such as the CDC, ACIP, American Academy of Family Physicians, American College of
Nurse-Midwives, American Academy of Pediatrics, and ACOG (NFID, 2014). The
providers are invested in providing the best care to every patient as outlined by the
Banner Health (2016a) mission and vision, ensuring the sustainability of this
intervention.
Evaluation Plan
After IRB approval was obtained (see Appendix H), initiation of this project
started with a retrospective chart review of every patient who received her prenatal care
through North Colorado Family Medicine between October 2012 and December 2015.
The only feasible way of obtaining the data needed for evaluation of this project was
through individual chart review. The office manager pulled all of the delivery codes for
the specified time frame and provided the names and birthdays of those patients for chart
review. The chart review provided a baseline percentage of patients who received the
Tdap during pregnancy after release of the national recommendations (CDC, 2013b). It
was anticipated that compliance would have increased since the national
recommendations for Tdap in every pregnancy were published so an average of the years
2013, 2014, and 2015 were calculated and reported as the baseline percentage of
compliance. Patient confidentiality was maintained throughout the process by only
conducting reviews in the clinic setting through a secure database after obtaining written
permission from the office manager. No identifying markers were used in this process,
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no patient identifiers were recorded, and the identity of all patient health information was
kept confidential by clinic and organizational standards.
Establishing a Baseline: National
Rates
National rates of Tdap uptake during pregnancy have fluctuated based on
different factors including year, location, socioeconomic status, and ethnicity. National
studies have found uptake of Tdap during pregnancy between 14.3%-55.7%, depending
on the size and location of the populations measured (Ahluwalia et al., 2015; Harriman &
Winter, 2014; Housey et al., 2014). These studies also found the lower percentages of
Tdap vaccine uptake were associated with the amount and quality of prenatal care
received.
Establishing a Baseline: County and
State Rates in Colorado
No data were available on the rates of Tdap vaccination during pregnancy in
Colorado; thus, there was no way to determine if the percentage determined by chart
review of patients receiving prenatal care at North Colorado Family Medicine was
representative of county or state rates. There was speculation that women who received
the vaccine from a family practice clinic had higher uptake rates versus those who
received their prenatal care at an OB/GYN due to the availability of vaccines in the
primary care setting (Cherry, 2015). This speculation was based on the fact that the
United Kingdom has had higher vaccine uptake rates since their recommendation to start
vaccinating all women with Tdap in 2013 and the majority of women in the United
Kingdom received their prenatal care through family practice clinics versus OB/GYNs
(Cherry, 2015).
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The retrospective chart review established a baseline from which the overall
vaccine improvement rates could be measured. The percentage measured for evaluation
of the intervention was not an accurate representation of the overall increase in vaccine
rates because of the short project timeframe relative to the overall length of pregnancies.
The intervention timeframe was 10 weeks; since it was unknown how many pregnant
patients would be appropriate for the Tdap vaccine during this timeframe, an additional
evaluation method was used to measure the outcomes of the three objectives. Each
objective was measured by a separate post-intervention survey. Each survey included
two questions that were measured by a 5-point Likert scale with the following answer
options: Strongly Agree, Agree, Neutral, Disagree, and Strongly Disagree. The two
provider surveys were combined into one to minimize the use of clinic resources.
Examples of each survey can be found in Appendix J.
Evaluation Method for Objective
One
The first objective was to update and improve current practice to increase the rate
of Tdap immunizations in pregnant women at North Colorado Family Medicine. This
objective was met by updating and improving an existing provider reminder system that
was well established in current practice. The expected outcome of this intervention was
to improve Tdap vaccination rates in pregnant patients by reminding providers to offer
the vaccine. It was evaluated in two ways: (a) pre- and post-intervention chart reviews of
Tdap vaccine rates in pregnant women seen at North Colorado Family Medicine and (b)
post-intervention provider survey assessing use of implemented reminder tool (see
Appendix J).

47
Once the pre-intervention baseline percentage of Tdap immunization rates during
pregnancy was established, then evaluation of the intervention was done through postintervention chart review. This method was described in detail earlier in this section and
the expected outcome of this intervention was an increase in the rate of Tdap
immunizations during pregnancy. A secondary method of evaluation was used to assess
the usefulness of the updated provider reminder tool by using a post-intervention provider
survey. This survey was measured on a 5-point Likert scale (see Appendix J) and
included two statements:
1.

This tool will be useful in reminding you to facilitate the administration of
the Tdap vaccine in every pregnant patient at 27-36 weeks.

2.

This updated tool will be beneficial in current practice.

Evaluation Method of Objective
Two
The second objective was to increase provider awareness and compliance with the
national recommendations of providing every pregnant patient with a Tdap vaccine
between 27 and 36 weeks gestation. This objective was met by placing a patient
education sheet in the patient education packet distributed to every patient and discussed
in detail by providers at initial appointment. There were two expected outcomes for this
intervention: (a) initiate a reminder to providers to discuss safety and efficacy of the Tdap
vaccine and to make an initial recommendation to have the vaccine given during an office
visit between 27 and 36 weeks, and (b) increase uptake of the Tdap vaccine during
pregnancy. The post-intervention chart review was the primary method of evaluation for
each objective and the secondary method of evaluation for each individual objective was
the post-intervention survey. For this objective, the providers were given a survey
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measured on a 5-point Likert scale (see Appendix J) that included the following
statements:
1.

The Tdap in pregnancy educational material reminded you to discuss the
vaccine with your patients during the OB intake.

2.

This educational material will be beneficial in current practice.

Evaluation Method for Objective
Three
The third objective was to increase medical assistant awareness and compliance
with the current standing order of administering the Tdap vaccine to all pregnant patients.
This objective was met by providing education to the medical assistants regarding the
existence of an adult vaccine standing order. This standing order was already in use at
the clinic prior to the intervention. The intervention focused on educating all MAs to its
existence with additional education regarding when the vaccine should be given and what
steps to take if the patient should refuse. The expected outcome of this intervention was
an increase in the rates of Tdap vaccines given and was evaluated by comparison of preand post-intervention chart review and post-intervention survey evaluating the
educational sessions and how they improved the use of the current clinic standing order.
Evaluation of this last objective--increasing MA compliance with the existing standing
order--was measured by a Likert scale similar to the provider survey (see Appendix J)
that included the following questions.
1.

Prior to the educational session, were you aware that it is within the scope of
your practice to initiate the Tdap vaccine in all pregnant women between 27
and 36 weeks?
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2.

After the educational session provided, will you now administer the Tdap
vaccine to every pregnant woman between 27 and 36 weeks?

3.

If a patient refuses the Tdap vaccine, will you refer this refusal to the
patient’s provider to provide additional education about the vaccine?

Each intervention was targeted at a specific point in the care of the pregnant
patient where there would be the greatest chance for omission of the national
recommendation to administer the Tdap vaccine to every pregnant patient between 27
and 36 weeks. To this end, each objective was evaluated with a comparison of postintervention vaccine rates with pre-intervention vaccine rates. The post-intervention rates
were measured at the end of the 10-week intervention period and are reported in the
following chapter. Each individual objective was then measured by provider and MA
surveys and reported as a percentage of providers and MAs who indicated agreement
with the intervention as (a) beneficial to practice, (b) neutral, and (c) did not find the
intervention beneficial.
Institutional Review Board
This quality improvement (QI) project was approved by the IRB at the University
of Northern Colorado (see Appendix H). As this QI project did not involve collecting
data from human subjects, only medical records including pre- and post-intervention
chart review of existing pregnant patients, it was granted expedited status. Education
provided to the pregnant patients during the OB uptake and to the medical assistants
during monthly meetings was already standard practice in the clinical setting so no
addition resources were needed. North Colorado Family Medicine is a medical residency
program where each doctor is required to do a similar capstone project to complete his or
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her residency. Due to the large volume of capstone projects completed through NCFM
every year, the medical director, representing the Banner system, had implemented a
review system that gave the medical director of the clinic authority to determine if a
project was exempt from IRB review through Banner Health. Per the medical director of
NCFM, this capstone met requirements to be exempt from review through the Banner
Health IRB. Any information obtained through the clinic for use within this project
remains confidential to protect the patients as well as the integrity of the clinic. Further,
any data reported about the project were group or aggregate data and did not involve
patient or staff identifying information.
Summary
Pertussis is highly contagious but preventable due to the widespread use of
vaccines. The national recommendation (CDC, 2013b) to immunize every pregnant
woman as a method for protecting unborn infants was released in 2012 yet nationwide
uptake has remained low. This QI project was aimed at improving and updating existing
practices at North Colorado Family Medicine to align with the national recommendation.
National and international research offered evidence to support the use of the Tdap
vaccine during pregnancy as a method of reducing the burden of the pertussis illness on
newborns and infants. The benefits of this QI project included providing passive
immunity to newborns and infants for pertussis, offering additional protection to mothers,
and increasing provider awareness of the importance of providing the Tdap in every
pregnancy.
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CHAPTER IV

RESULTS AND OUTCOMES

The purpose of this project was to improve the rates of Tdap in the pregnant
population at North Colorado Family Medicine (NCFM) in Greeley, Colorado. The
recommendation to providers to give a Tdap in every pregnancy was published in
October 2012 by the Centers for Disease Control (2013b) in conjunction with the
American Council for Immunization Practices. This project was targeted at improving
the rates of Tdap vaccines given to pregnant women by offering education and reminders
to clinic providers and medical assistants (MA) as the available literature suggested
provider recommendation offered the highest success rates for improving Tdap rates in
other settings.
Three specific and measurable objectives were implemented:
1. Update and improve current practice to increase the rate of Tdap
immunizations in pregnant women at North Colorado Family Medicine.
2. Increase provider awareness and compliance with the national
recommendations of providing every pregnant patient with a Tdap vaccine
between 27 and 36 weeks gestation.
3. Increase medical assistant awareness and compliance with current standing
order to administer all pregnant patients with Tdap vaccine.
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The first step in the evaluation process was to determine the population of
pregnant women seen in the clinic to predict sustainability and generalizability in the
general population. In 2015, there were 18,650 patient visits at NCFM with 2,035 of
those visits coded for pregnancy. This number was only an approximation but aligned
with the pre-intervention estimate that the pregnant population accounted for roughly
11% of the patient population in northern Colorado.
It was anticipated the rate of compliance with the national recommendations
would fluctuate after the new recommendation was implemented in October 2012.
Therefore, to determine a pre-intervention baseline, the average rates for 2013, 2014, and
2015 were examined. Pre-intervention vaccine rates were computed by individual chart
review after delivery codes were provided by the clinic office manager. In 2013, there
were 112 deliveries; 65 of those women were given the Tdap vaccine and 47 women did
not receive the vaccine for a compliance rate of 58%. In 2014, there were 145 total
deliveries; 99 of those women were given the Tdap vaccine and 46 women did not
receive the vaccine for a compliance rate of 68%. In 2015, there were 137 deliveries; 110
of those women were given the Tdap vaccine and 27 did not receive the vaccine for a
compliance rate of 80%. As predicted, there was a steady increase in compliance from
the publication of the national recommendation (CDC, 2013b). The average of those
three years (69%) was used as the pre-intervention baseline as this was estimated to more
likely represent the general population.
It is important to note the delivery codes were only provided for Banner
associated hospitals; thus, women who received care at NCFM but delivered outside of
the system were excluded. Another confounding variable included women who might
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have been given the vaccine at another location or might have received prenatal care from
an unassociated provider.
Outcomes of Objectives
Objective One
The first objective was to update and improve current practice to increase the rate
of Tdap immunizations in pregnant women at North Colorado Family Medicine. This
objective was accomplished by updating a pre-existing provider checklist to include a
reminder to give the Tdap vaccine between 27 and 36 weeks. This objective was
measured by evaluation and comparison of pre- and post-intervention vaccine rates in
pregnant women. The established baseline pre-intervention compliance rate was 69%.
Post-intervention chart review included 74 patients who received prenatal care in the
intervention time frame. Of the 74 pregnant patients seen in the intervention timeframe,
65 received the Tdap vaccine for a compliance rate of 88%.
The second method of evaluation to measure the outcomes of objective one was
with a post-intervention provider survey to assess whether or not the providers found this
updated checklist beneficial by asking the following two questions:
1.

Will this tool be useful in reminding you to facilitate the administration of
the Tdap vaccine in every pregnant patient at 27-36 weeks?

2.

Will this updated tool be beneficial in current practice?

This survey was measured on a 5-point Likert scale from 1 = Strongly disagree to 5 =
Strongly agree. Of the 35 surveys distributed to the faculty physicians, nurse
practitioners, and medical residents, 17 surveys were returned for a return rate of 49%.
All of the providers who returned the survey agreed or strongly agreed this updated
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checklist was a useful tool for reminding him or her to administer the Tdap vaccine at 2736 weeks of pregnancy.
Key facilitators. No education was required on the implementation or use of the
updated checklist because its use was already well-established in current practice. The
medical residents found this tool especially helpful in developing their practice with OB
patients as the checklist of tasks in the three trimesters can be overwhelming to
unexperienced providers. The faculty physicians and nurse practitioners informally
reported they appreciated the update as the new checklist and new paper color offered a
visual reminder to existence of the tool.
Key barriers. A few barriers were associated with this intervention including a
minor delay in the rollout process, the start of a new cohort of medical residents, and the
rollout of the new electronic health record. The new residents started the first week of
July, which was assumed to create a transient decrease in vaccine compliance that likely
improved after the first two to three weeks. There was a delay in the rollout of the
checklist as the nursing director took this opportunity to update other parts of it.
The last barrier was the implementation of the new electronic health record,
Cerner, which occurred three weeks into the intervention window. This was estimated to
be the most significant barrier and might have resulted in either inaccurate or reduced
post-intervention vaccine rates. The office manager pulled ICD-10 codes for pregnancy
related visits as well as the codes for administration of the Tdap vaccine. Possible
barriers related to this process included pregnant patients who received the vaccine where
there was missed documentation, women who were not given the vaccine at the
appropriate time related to the stress caused to the providers and MAs during the rollout
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process, or charts that were missed due to this author’s relative unfamiliarity with the
new electronic health record compared to the previous system. The significance of these
barriers on vaccine rates was unknown but there was likely only a minor decrease in rates
due to the relatively long intervention window.
Objective Two
The second objective focused on increasing provider awareness and compliance
with the national recommendation (CDC, 2013b) of providing every pregnant patient
with a Tdap vaccine between 27 and 36 weeks gestation. This objective was met by
placing a CDC (2015c) authored patient education sheet in the patient education packet
that was distributed to every patient. Standard practice in the clinic is the provider
discusses the content of the packet with each pregnant patient at the initial OB intake
visit. There were two expected outcomes for this intervention: (a) Providers would be
reminded to discuss safety and efficacy and make initial recommendations to be
vaccinated during an office visit between 27 and 36 weeks, and (b) administration rates
of the vaccine during pregnancy would increase. These objectives were measured by
evaluation and comparison of pre- and post-intervention vaccine rates in pregnant
women. The established baseline pre-intervention compliance rate was 69%. Postintervention chart review looked at 74 patients who received prenatal care in the
intervention time frame; 65 of 74 pregnant women received the vaccine for a compliance
rate of 88%.
The second method of evaluation to measure the outcomes of objective two was
with a post-intervention provider survey to assess whether or not the providers found this
updated checklist beneficial by asking the following two questions:
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1.

Did the Tdap in pregnancy educational material remind you to discuss the
vaccine with your patients during the OB intake?

2.

Will this educational material be beneficial in current practice?

This survey was measured on a 5-point Likert scale from Strongly disagree to Strongly
agree. Of the 35 surveys distributed to the faculty physicians, nurse practitioners, and
medical residents, 17 surveys were returned for a return rate of 49%. Of the 17 providers
who returned a survey, 15 agreed or strongly agreed the Tdap in pregnancy educational
material reminded them to discuss the vaccine with their patients at the initial intake
appointment and felt that this tool would be useful to their practice. One provider noted
he/she was not aware of the material and one provider left feedback that the timing of the
educational material was too early in the pregnancy to be useful.
Key facilitators. As with the first objective, this intervention focused on
updating and improving on existing practice. The use of the educational packet was
established practice and did not require any education for physicians and nurse
practitioners. The information sheet was free from the CDC (2015c) and did not require
any additional resources or special permission for use. This educational material targeted
the pregnant patient population and while acting as a reminder to the providers and had
the added benefit of providing additional education to patients and families. The
outcome of patient education was not in the scope of this capstone project and the benefit
is only predicted informally.
Key barriers. The barriers for achievement of this objective were much the same
as with the first objective with regard to the start of a new cohort of medical residents as
well as the switch to the new electronic health record. These barriers were expected to
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only minimally affect the outcomes of the chart review for compliance rates. There was a
slight cost in printing the new CDC educational material as the clinic did opt to print
these materials in colored ink for the benefit of the patients.
Objective Three
The third objective was implemented in an effort to increase medical assistant
awareness and compliance with the current standing order to administer the Tdap vaccine
to all pregnant patients. This objective was met by providing education to the medical
assistants regarding the existence of an adult vaccine standing order based on the most
current adult vaccine schedule. This vaccine schedule recommended administering the
Tdap to all pregnant patients between 27 and 36 weeks. The intervention focused on
educating all MAs to its existence with additional education regarding when the vaccine
should be given and what steps to take if the patient should refuse. The expected
outcome of this intervention was an increase in the rates of Tdap vaccines given and was
evaluated by comparison of pre- and post-intervention chart review and post-intervention
survey evaluating the educational sessions and how they improved the use of the current
clinic standing order. The established baseline pre-intervention compliance rate was
69%. Post-intervention chart review looked at 74 patients who received prenatal care in
the intervention time frame. Of the 74 patients reviewed, 65 women received the Tdap
vaccine for a compliance rate of 88%.
The second method of evaluation to measure the outcome of objective three was
with a post-intervention provider survey to assess whether or not the providers found this
updated checklist beneficial by asking the following two questions:
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1.

Prior to the educational session, were you aware that it is within the scope of
your practice to initiate the Tdap vaccine in all pregnant women between 27
and 36 weeks?

2.

After the educational session provided, will you initiate Tdap vaccine to
every pregnant woman between 27 and 36 weeks?

3.

If a patient refuses the Tdap vaccine, will you defer this refusal to the
patient’s provider to provide additional education about the vaccine?

This survey was measured on a 5-point Likert scale from Strongly disagree to Strongly
agree. Of the 12 surveys distributed to the medical assistants, nine surveys were returned
for a return rate of 75%. Nine of the nine MAs agreed or strongly agreed the educational
sessions helped them feel more empowered to initiate the Tdap vaccine to pregnant
patients between 27 and 36 weeks gestation. Of the nine surveys returned by the medical
assistants, seven were not aware of the standing order to give this vaccine prior to the
educational session but post-intervention survey results showed all MAs would initiate
the Tdap vaccine during pregnancy. All of the medical assistants who returned surveys
agreed or strongly agreed to defer all refusals to the patient’s provider for further
education. This researcher felt this last piece of the intervention was especially important
as vaccine refusals had not always been reported to the providers; the literature indicated
provider education and recommendation had the highest rate of success for improving
vaccine administration rates.
Key facilitators. This objective was relatively easy to accomplish as the
education provided to the medical assistants was done at mandatory monthly meetings
and did not require any additional time at the clinic. The medical assistants were paid for
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this educational session as it was mandatory. The PowerPoint was made by this
researcher prior to the educational meeting, did not utilize any clinic resources, nor was it
associated with any added cost. The presentation was built into the meetings by the
nursing director and did not detract from any additional clinic education.
Key barriers. The barriers for achieving this objective were much the same as
the first two objectives with regard to the switch to the new electronic health record. The
new workflow process with the new electronic health record required the providers to
order all vaccines given whereas previous workflow allowed for the MAs to order
vaccines given. It was assumed to be a barrier in the overall outcome of vaccine rates as
there were likely fallouts in the ordering and documentation of the vaccine
administration. Another barrier likely affecting the overall outcomes of this objective
was the high turnover rate of MAs in the office.
Unintended Consequences
This capstone project had the overall intention of improving the Tdap rates in
pregnancy to offer passive immunity and indirectly decrease the morbidity and mortality
rates associated with pertussis in newborns and infants. It was out of the scope of this
capstone to measure any associated decrease in pertussis rates in this age group but any
indirect decrease in pertussis rates was considered a positive consequence of this project.
Due to the seasonal timing of this intervention, it was not possible to include a
strategy to improve influenza vaccine rates in pregnant women. At the request of the
nursing director, a reminder to give the influenza vaccine at any stage in pregnancy
during flu season was added to the provider checklist (see Appendix B). There was no
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way of estimating the unintended consequences of this intervention but it was assumed
this would only be a benefit to the providers and patients.
Summary
The results of this intervention showed an increase in the rates of Tdap given to
the pregnant population seen at North Colorado Family Medicine. The medical assistants
provided positive feedback that the educational sessions provided were beneficial. The
MAs provide the majority of the vaccines to patients in the clinic and are often the first
line in initiating the recommendation for vaccination. The providers, while having a
baseline understanding of the purpose of giving the Tdap during pregnancy, are often so
busy they might forget to order the vaccine. Providers who returned surveys all agreed or
strongly agreed the updated checklist and patient education sheet would be helpful as a
reminder in practice to order the Tdap vaccine. Collectively, the intervention was
successful at increasing the rates of Tdap provided to pregnant women in Greeley,
Colorado with the overall goal of reducing pertussis rates in the infant population and
reducing the morbidity and mortality of a vaccine preventable disease.
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CHAPTER V

RECOMMENDATIONS AND IMPLICATIONS
FOR PRACTICE

North Colorado Family Medicine (NCFM), as a representative of Banner Health
in the northern region of Colorado, prides itself on providing the most up-to-date and
evidence-based care to patients and the community. This project targeted only a small
and specific population in Northern Colorado but was predicted to have rippling benefits.
The topic of vaccinations in any population remains a controversial one with patient
opinions and decisions based on ever-expansive access to the internet. Despite the
opinions of some, vaccinations remain one of the single most effective methods of
disease prevention in the general public. Data in this project supported individuals
educated by their healthcare professionals are more likely to agree to be immunized.
With the culture of health care being focused on prevention, the job of providing
expansive preventive care rests primarily on the shoulders of primary care providers.
Projects such as this capstone could help improve outcomes in the primary care setting by
improving access to and offering reminders for health promotion and disease prevention.
Recommendations for North Colorado Family Medicine
One of the benefits of this project was the ease with which it could be maintained,
sustained, and applied to the general population. This project focused on improving wellestablished and current practice by revising and improving existing tools used in provider
practice. The provider reminder checklist and patient education factsheet are now
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established and will remain in use after the conclusion of this project. A further
recommendation that could improve pregnancy outcomes would be the inclusion of an
influenza factsheet in the patient packet along with the pertussis factsheet. This project
offered other avenues for projects to improve overall vaccine rates and preventive care
provided to the Greeley community. Each medical resident is also required to do a
capstone project at the end of their third year at the clinic, which offers unlimited
opportunities for process improvement. With medicine changing at such a fast pace,
clinics such as NFCM, which are so readily willing to adopt new ideas and/or improve
current practice, will have better outcomes that will not only affect the patient population
but the community at large.
A limitation noted in Chapter IV discussed the outcomes of objective three being
confounded by the high rate of medical assistant turnover at NCFM. In the 14-week span
of time from the initiation of the project, there was a large turnover in MAs at the clinic
and this rate of turnover is not expected to slow down. It was determined that a third
educational session given in the 14week intervention window would have been beneficial
to cover for the unpredicted turnover that occurred. In an effort to push for sustainability,
the educational PowerPoint was provided to the nursing director for future education of
new MAs. In discussing this with the nursing director, this high turnover rate is not
uncommon as this job can often be considered a stepping stone to other roles in health
care. Influence on vaccination rates by the MAs at NCFM will require ongoing
education to the incoming staff by the nursing director, providers, and existing MAs. It is
the recommendation of this researcher that the presentation be given quarterly at
mandatory staff meetings as well as being incorporated into the MA new hire orientation.
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This will offer reminders to existing staff as well as providing education to any new and
incoming MAs.
Possible Applications in Other Settings
With the ease of sustainability of this project at NCFM, this author believes this
project can be expanded. The CDC website has ample educational material available at
no charge including a toolkit available to all providers for increasing Tdap vaccination
rates in pregnancy and educational materials for patients, families, and members of the
community. Examples of this include posters that can be strategically placed in clinic
waiting rooms and exam rooms, scripting resources for providers to answer questions
about the safety and efficacy of the vaccine, and tips for coding immunizations to ensure
the clinic receives reimbursement for the Tdap vaccine.
As a member of Banner Health, a large multi-state health system with sites in
Nebraska, Arizona, Colorado, Alaska, California, Nevada, and Wyoming, this project
could be disseminated throughout the system to other clinic sites, targeting a wider group
of pregnant women with the intention of having a greater impact on pertussis rates in the
western United States. As discussed in Chapter I, this project aligned with Banner
Health’s (2016b) strategic plan for providing high quality and excellent care to all of its
patients. As of October 2012, best practice in the care of pregnant women is to provide
the Tdap vaccination between 27 and 36 weeks. Banner Health’s strategic plan involves
acting on opportunities and change, constantly improving care, and focusing on
protecting one of our most vulnerable populations.
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Contribution to Personal Leadership Goals
This researcher sees the role of the Doctor of Nursing Practice (DNP) as having a
substantial impact on illness prevention and health promotion in the future of health care.
It was the goal of this DNP candidate to work toward shifting the focus to primary
prevention in a population health setting. Projects such as this that target a vulnerable
population have the ability to have a larger and more substantial impact on the future of
health care. It was this researcher’s goal to use the knowledge and experience gained
through the implementation of this project to implement future population-focused illness
prevention and health promotion projects in rural settings in need of such expertise.
Projects such as this one have the ability to expand and grow, leading to a ripple effect
that has the ability to make a significant impact on the lives of those it affects. If this
project prevented even one infant from contracting pertussis, then that impact will have
made enough of a difference in the lives of individuals otherwise affected. Thus, this
researcher’s goal of having a positive impact on the community will have been reached.
Summary
Pertussis is highly contagious and can lead to costly hospitalizations and even
death in infants less than three months old but is preventable with vaccines. Available
literature and research are overwhelmingly in support of the safety and efficacy of the
Tdap vaccine during pregnancy. Mothers use their own immune system to create
antibodies that will protect their infants through the first few months of life and providers
are in a unique position to improve vaccine rates through education and recommendation.
This project targeted individual pregnant patients with the goal of impacting the
greater community through the reduction of pertussis rates in the population most
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vulnerable and susceptible to the high rates of morbidity and mortality. This project used
a quality improvement process directly aimed at established practices as well as provider
and patient education to bring about practice improvement. Vaccines remain one of the
best tools for improving community and population health. By circling the wagons
around infants, families and communities will be strengthened by the outcomes of
improving immunization rates in pregnant women. Infants are susceptible to pertussis; it
is up to parents, providers, and the community at large to offer protection to this
vulnerable population.
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APPENDIX A
PROVIDER REMINDER TOOL CURRENTLY USED
IN PRACTICE
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Prenatal care highlights
Initial visit from 5-11 weeks:
Labs including CBC, Hep B, HIV, RPR, Blood type/Rh, urine culture, STI
Medical history
Obstetric history including # deliveries and types, PPH, DM, complications
Establish an idea of pregnancy risk
Ge early U/S for dating (not the pregnancy resource center)
Education/community referrals
Next visit is OB PE;
Pap if indicated
STI
Second Trimester:
Quad screen at 16-19 weeks. Sometimes needs to be recalculated based on EDC
Dating u/s if not done already
U/S for anatomy at 19-22 weeks
Referral to MFM if determined high risk (quad screen should be done first)
Fetal movement
Immunizations
Third Trimester:
26 weeks: glucose screen; 1 hour to be done on high-risk patients
28-28 weeks: Rhogam if needed; recommended to repeat Ab screen
32 weeks: h/h for anemia and treat if necessary
34 weeks: Consider repeat 3 hour GTT if the first was mildly abnormal
Tubal papers if appropriate
37 weeks: GBS to be done if not already positive
NST as indicated: DM, GDM, post-dates, IUGR etc.
Other things to consider:
*When a positive Chlamydia is obtained anytime, a repeat test of cure needs to be done
four weeks later
*GBS is good for five weeks; you may need to repeat it if your patient goes post-dates
*Trace to 1+ protein during the pregnancy is likely related to dehydration and does not
need a work-up
*In patient with a history of genital herpes, recommend prophylactic treatment starting
about 36 weeks to decrease the chance of outbreak at time of delivery.
*If patient is high risk for HIV (eg; hx of drug abuse), then recommend a repeat HIV to
be done at 36 weeks.
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APPENDIX B
UPDATED PROVIDER REMINDER TOOL TO INCLUDE
TETANUS, DIPHTHERIA, ACELLULAR PERTUSSIS
VACCINATION
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Prenatal care highlights
Initial visit from 5-11 weeks:
o Labs including CBC, Hep B, HIV, RPR, Blood type/Rh, urine culture, STI
o Medical history
o Obstetric history including # deliveries and types, PPH, DM, complications
o Establish an idea of pregnancy risk
o Ge early U/S for dating (not the pregnancy resource center)
o Education/community referrals
Next visit is OB physicial
o Pap if indicated
o STI
Second Trimester:
o Quad screen at 16-19 weeks. Sometimes needs to be recalculated based on EDC
o Dating U/S if not done already
o U/S for anatomy at 19-22 weeks
o Referral to MFM if determined high risk (quad screen should be done first)
o Fetal movement
**IMMUNIZATIONS**
 Influenza Vaccine given anytime in pregnancy during flu season
 Tdap vaccine given 27-36 weeks despite previous vaccine status
Third Trimester:
o 26 weeks: glucose screen; 1 hour to be done on high-risk patients
o 28-28 weeks: Rhogam if needed; recommended to repeat Ab screen
o 32 weeks: h/h for anemia and treat if necessary
o 34 weeks: Consider repeat 3 hour GTT if the first was mildly abnormal
o Tubal papers if appropriate
o 37 weeks: GBS to be done if not already positive
o NST as indicated: DM, GDM, post-dates, IUGR etc.
Other things to consider:
 When a positive Chlamydia is obtained anytime, a repeat test of cure needs to be done
four weeks later
 GBS is good for five weeks; you may need to repeat it if your patient goes post-dates
 Trace to 1+ protein during the pregnancy is likely related to dehydration and does not
need a work-up
 In patient with a history of genital herpes, recommend prophylactic treatment starting
about 36 weeks to decrease the chance of outbreak at time of delivery.
 If patient is high risk for HIV (eg hx of drug use), then recommend a repeat HIV to be
done at 36 weeks.
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CENTERS FOR DISEASE CONTROL AND PREVENTION
PATIENT EDUCATIONAL MATERIAL
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APPENDIX D
STANDING ORDER FOR ADULTS AND ADOLESCENTS
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APPENDIX E
ADULT VACCINATION SCHEDULE
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APPENDIX J
PROVIDER AND MEDICAL ASSISTANT SURVEYS
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH
UNIVERSITY OF NORTHERN COLORADO
Project Title: Working towards Tdap in Every Pregnancy: Protecting Our Most
Vulnerable Population
Researchers: Jessica M. Scott (BSN-DNP Student), School of Nursing
e-mail: mayh3489@bears.unco.edu
The aim of this process improvement project is to improve Tdap rates in pregnant
patients at North Colorado Family Medicine. This project is targeted at increasing the
rates of provider recommendations for Tdap immunizations during pregnancy. This
project will include two components that target providers: 1) an update to the prenatal
highlights provider reminder tool that is located in the OB chart, and 2) a CDC authored
factsheet on the safety and efficacy of the Tdap vaccine in pregnancy that will be placed
in the patient education packet to be handed out at the OB intake visit.
All surveys will be distributed to provider clinic mailboxes and will be returned to the
Dottie Schulte’s clinic mailbox upon completion. It is anticipated that it will take you
approximately 2-3 minutes to complete the survey.
The purpose of this survey is to evaluate the effectiveness of the updated prenatal
highlights tool to include a reminder for Tdap immunization in pregnancy, and the
addition of a CDC authored Tdap in pregnancy factsheet into the OB intake education
packet as reminder tools for providers to make the recommendation for Tdap in every
pregnant patient at North Colorado Family Medicine. Participation is voluntary and
your responses will be anonymous. There are no foreseeable risks to participants, as this
is a process improvement project of a current program already in place and is based on
national vaccine recommendations. Participants may benefit directly from this project by
ensuring that best practice is followed based on national recommendations to vaccinate
every pregnant patient with the Tdap vaccine between 27 and 36 weeks.
Participation is voluntary. You may decide not to participate in this study and if you begin
participation you may still decide to stop and withdraw at any time. Your decision will be
respected and will not result in loss of benefits to which you are otherwise entitled.
Having read the above and having had an opportunity to ask any questions, please access
and complete the attached document “Improving Tdap Rates in Pregnancy: Provider
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Survey”. Return completed surveys to Dottie Schulte’s mailbox. If at any time you have
any questions please contact one of the undersigned. By completing the questionnaire,
you will give us permission for your participation. You may keep this form for future
reference. If you have any concerns about your selection or treatment as a research
participant, please contact Sherry May, IRB Administrator, Office of Sponsored
Programs, Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970-3511910.
Dottie Schulte FNP-BC
dottie.schulte@bannerhealth.com
970-810-2710

Jessica Scott, DNP (c), RN, BSN
mayh3489@bears.unco.edu
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Improving Tdap Rates in Pregnancy
Provider Survey

Updated Provider Reminder Tool
Strongly Disagree Neutral
Disagree

Agree

Strongly
Agree

This tool will be useful in reminding
you to facilitate the administration of
the Tdap vaccine in every pregnant
patient at 27-36 weeks

1

2

3

4

5

This updated tool will be beneficial in
current practice

1

2

3

4

5

CDC Patient Educational Material
Strongly Disagree Neutral
Disagree

Agree

Strongly
Agree

The Tdap in pregnancy educational
material reminded you to discuss the
vaccine with your patients during the
OB intake

1

2

3

4

5

This educational material will be
beneficial in current practice

1

2

3

4

5
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH
UNIVERSITY OF NORTHERN COLORADO
Project Title: Working towards Tdap in Every Pregnancy: Protecting Our Most
Vulnerable Population
Researchers: Jessica M. Scott (BSN-DNP Student), School of Nursing
e-mail: mayh3489@bears.unco.edu
The aim of this process improvement project is to improve Tdap rates in pregnant
patients at North Colorado Family Medicine. This project is targeted at increasing the
rates of Tdap immunizations during pregnancy by empowering Medical Assistants to
initiate the immunization process. At the end of the education session(s), the Medical
Assistants will be able to verbalize the purpose of the Tdap vaccine during pregnancy, the
window of pregnancy in which the immunization can be given (27-36 weeks), and the
process if a patient or family member should decline the vaccine. This project will target
Medical Assistants at North Colorado Family Medicine through education provided at
regularly scheduled monthly staff meetings.
All surveys will be distributed to individual Medical Assistant clinic mailboxes and will
be returned to the Dottie Schulte’s clinic mailbox upon completion. It is anticipated that it
will take you approximately 2-3 minutes to complete the survey.
The purpose of this survey is to evaluate the effectiveness of the education provided to
Medical Assistants regarding the purpose and process of administering the Tdap
immunization in every pregnant patient at North Colorado Family Medicine between 27
and 36 weeks, and if the vaccine should be declined, deferring education back to the
provider to offer additional education, and make further recommendations. Participation
is voluntary and your responses will be anonymous. There are no foreseeable risks to
participants, as this is a process improvement project of a current program already in
place and is based on national vaccine recommendations. Participants may benefit
directly from this project by ensuring that best practice is followed based on national
recommendations to vaccinate every pregnant patient with the Tdap vaccine between 27
and 36 weeks.
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Participation is voluntary. You may decide not to participate in this study and if you begin
participation you may still decide to stop and withdraw at any time. Your decision will be
respected and will not result in loss of benefits to which you are otherwise entitled.
Having read the above and having had an opportunity to ask any questions, please access
and complete the attached document “Improving Tdap Rates in Pregnancy: Provider
Survey”. Return completed surveys to Dottie Schulte’s mailbox. If at any time you have
any questions please contact one of the undersigned. By completing the questionnaire,
you will give us permission for your participation. You may keep this form for future
reference. If you have any concerns about your selection or treatment as a research
participant, please contact Sherry May, IRB Administrator, Office of Sponsored
Programs, Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970-3511910.
Dottie Schulte FNP-BC
dottie.schulte@bannerhealth.com
970-810-2710

Jessica Scott, DNP (c), RN, BSN
mayh3489@bears.unco.edu
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Medical Assistant Survey
Medical Assistant Educational Session
Strongly Disagree Neutral
Disagree
Prior to the educational session you
were aware that it is within the scope of
your practice to initiate the Tdap
vaccine in all pregnant women between
27 and 36 weeks

Agree

Strongly
Agree

1

2

3

4

5

After the educational session provided,
you will now initiate Tdap vaccine to
every pregnant woman between 27 and
36 weeks

1

2

3

4

5

If a patient refuses the Tdap vaccine,
you will defer this refusal to the
patient’s provider to provide additional
education about the vaccine

1

2

3

4

5

